Updating results

6680 results Sort: Relevance | Date

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)

This guidance has been withdrawn

Technology appraisal guidance Published June 2017 Withdrawn

Oral health in care homes (QS151)

Evidence-based statements to deliver quality improvements in oral health, including dental health and daily mouth care, for adults in care homes

Quality standard Published June 2017

Haematological cancers (QS150)

Evidence-based statements to deliver quality improvements in managing haematological cancers (cancer of the blood, bone marrow or lymph nodes) in all age groups

Quality standard Published June 2017

Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults

Technology appraisal guidance Published May 2017

Eating disorders: recognition and treatment (NG69)

Evidence-based recommendations on assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders

NICE guideline Published May 2017

Osteoporosis (QS149)

Evidence-based statements to deliver quality improvements in managing osteoporosis in adults, including assessing risk and preventing fragility fractures

Quality standard Published April 2017

Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)

Evidence-based recommendations on pegylated liposomal irinotecan (Onivyde) for treating pancreatic cancer after gemcitabine

Technology appraisal guidance Published April 2017

Sexually transmitted infections: condom distribution schemes (NG68)

Evidence-based recommendations on condom distribution schemes to help reduce sexually transmitted infections (STIs) in all populations and prevent

NICE guideline Published April 2017

Managing medicines for adults receiving social care in the community (NG67)

Evidence-based recommendations on medicines support for adults (aged 18 and over) who are receiving social care in the community

NICE guideline Published March 2017

Mental health of adults in contact with the criminal justice system (NG66)

Evidence-based recommendations on assessing, diagnosing and managing mental health problems for adults who are in contact with the criminal justice system

NICE guideline Published March 2017

Care of dying adults in the last days of life (QS144)

Evidence-based statements to deliver quality improvements in the care of dying adults (aged 18 and over) in the last 2 to 3 days of life

Quality standard Published March 2017

Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma (kidney cancer) after previous treatment

Technology appraisal guidance Published February 2017

Head and neck cancer (QS146)

Evidence-based statements to deliver quality improvements in assessing, diagnosing and managing head and neck cancer in young people and adults

Quality standard Published March 2017

Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)

Evidence-based recommendations on immunohistochemistry/microsatellite instability testing to guide tests for Lynch syndrome in people with colon cancer

Diagnostics guidance Published February 2017

Drug misuse prevention: targeted interventions (NG64)

Evidence-based recommendations on targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines

NICE guideline Published February 2017

Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults

Technology appraisal guidance Published March 2017

Apremilast for treating active psoriatic arthritis (TA433)

Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis in adults

Technology appraisal guidance Published February 2017

Mepolizumab for treating severe refractory eosinophilic asthma (TA431)

Evidence-based recommendations on mepolizumab (Nucala) for treating severe refractory eosinophilic asthma in adults

Technology appraisal guidance Published January 2017

Blood transfusion (QS138)

Evidence-based statements to deliver quality improvements in the general principles of blood transfusion in adults, young people and children over 1 year old

Quality standard Published December 2016

Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)

Technology appraisal guidance Published December 2016

HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)

Evidence-based recommendations on increasing the uptake of testing among people who may have undiagnosed HIV

NICE guideline Published December 2016

Coexisting severe mental illness and substance misuse: community health and social care services (NG58)

Evidence-based recommendations on improving services for people aged 14 and above with coexisting severe mental illness and substance misuse

NICE guideline Published November 2016

Mental wellbeing and independence for older people (QS137)

Evidence-based statements to deliver quality improvements to maintain or improve the mental wellbeing and independence of people aged 65 or over

Quality standard Published December 2016

Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)

Evidence-based recommendations on changing people's behaviour (including use of antibiotics and preventing infection) to reduce antimicrobial resistance

NICE guideline Published January 2017

Cerebral palsy in under 25s: assessment and management (NG62)

Evidence-based recommendations on diagnosing, assessing and managing cerebral palsy in children and young people under 25

NICE guideline Published January 2017

Physical health of people in prison (NG57)

Evidence-based recommendations on assessing, diagnosing and managing physical health problems of people in prisons or young offenders' institutions

NICE guideline Published November 2016

Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)

Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults

Technology appraisal guidance Published January 2017

Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic PD-L1-positive non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published January 2017

Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)

Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults

Technology appraisal guidance Published January 2017

Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults

Technology appraisal guidance Published December 2016

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

Technology appraisal guidance Published December 2016

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive breast cancer in adults

Technology appraisal guidance Published December 2016

Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for unresectable or metastatic melanoma in adults with a BRAF V600

Technology appraisal guidance Published October 2016

Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)

Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor

Technology appraisal guidance Published October 2016

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

Technology appraisal guidance Published December 2016

Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults

Technology appraisal guidance Published December 2016

End of life care for infants, children and young people with life-limiting conditions: planning and management (NG61)

Evidence-based recommendations on managment of end of life care for infants, children and young people (aged 0–17 years) with life-limiting conditions

NICE guideline Published December 2016

Low back pain and sciatica in over 16s: assessment and management (NG59)

Evidence-based recommendations on assessing and managing low back pain and sciatica in people aged 16 and over

NICE guideline Published November 2016

Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults

Technology appraisal guidance Published November 2016